Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeraj Narula

Showing results (81-90 of 204) with videos related to

Pageof 21
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 16, 2023
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center studyTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 31, 2024
Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's diseaseTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive Diseases and Sciences|February 19, 2026
Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENTEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Inflammatory Bowel Diseases|September 25, 2025
Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 27, 2022
Predictors of Placebo Induction Response and Remission in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|August 3, 2022
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Plos One|May 28, 2020
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysisJohan Burisch, Wolfgang Eigner, Stefan Schreiber, et al.
Scandinavian Journal of Gastroenterology|August 1, 2022
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitisEmily Chu Lee Wong, Badar Hasan, Parambir S Dulai, et al.
Pageof 21

Showing results (81-90 of 204) with videos related to

Sort By:
Pageof 21
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 16, 2023
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center studyTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 31, 2024
Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's diseaseTalat Bessissow, Neeraj Narula, Christopher Ma, et al.
Digestive Diseases and Sciences|February 19, 2026
Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENTEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.
Inflammatory Bowel Diseases|September 25, 2025
Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 27, 2022
Predictors of Placebo Induction Response and Remission in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|August 3, 2022
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Plos One|May 28, 2020
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysisJohan Burisch, Wolfgang Eigner, Stefan Schreiber, et al.
Scandinavian Journal of Gastroenterology|August 1, 2022
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitisEmily Chu Lee Wong, Badar Hasan, Parambir S Dulai, et al.
Pageof 21